Reviewing Charles River Laboratories International (NYSE:CRL) & Ascendant Solutions (OTCMKTS:MYDP)

Ascendant Solutions (OTCMKTS:MYDP) and Charles River Laboratories International (NYSE:CRL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Earnings & Valuation

This table compares Ascendant Solutions and Charles River Laboratories International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendant Solutions	N/A	N/A	N/A	N/A	N/A
Charles River Laboratories International	$4.02 billion	2.58	$22.20 million	($1.56)	-135.00

Charles River Laboratories International has higher revenue and earnings than Ascendant Solutions.

Institutional & Insider Ownership

98.9% of Charles River Laboratories International shares are held by institutional investors. 31.6% of Ascendant Solutions shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Ascendant Solutions and Charles River Laboratories International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ascendant Solutions	N/A	N/A	N/A
Charles River Laboratories International	-2.07%	15.78%	7.02%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ascendant Solutions and Charles River Laboratories International, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendant Solutions	0	0	0	0	0.00
Charles River Laboratories International	1	4	10	0	2.60

Charles River Laboratories International has a consensus target price of $209.46, suggesting a potential downside of 0.54%. Given Charles River Laboratories International’s stronger consensus rating and higher probable upside, analysts clearly believe Charles River Laboratories International is more favorable than Ascendant Solutions.

Summary

Charles River Laboratories International beats Ascendant Solutions on 7 of the 9 factors compared between the two stocks.

About Ascendant Solutions

Dougherty's Pharmacy, Inc. focuses on acquiring, managing, and growing community based pharmacies in the Southwest Region of the United States. Its flagship store is Dougherty's Pharmacy, a turn-key multi-service pharmacy located in Dallas, Texas. The company was formerly known as Ascendant Solutions, Inc. and changed its name to Dougherty's Pharmacy, Inc. in May 2017. Dougherty's Pharmacy, Inc. was founded in 1929 and is based in Dallas, Texas.

About Charles River Laboratories International

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.